Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Aurora Cannabis Stocks Needs More Legal Marijuana to Grow

By Chris Lau, InvestorPlace Contributor

Aurora Cannabis got a major tailwind when Canada became the second country to legalize marijuana, but ACB stock will need to continue growing to justify its stock price.

Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow

By Chris Lau, InvestorPlace Contributor

Mylan stock jumped ahead following quarterly earnings that impressed investors. Management will continue doing better than expected.

Biogen Stock Rebounds After Impressive Q3 Earnings

By Chris Lau, InvestorPlace Contributor

Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.

Why Micron Technology Stock Is Still Worth At Least $60

By Chris Lau, InvestorPlace Contributor

Micron stock bottomed at $35 recently, but a few key things have to happen first before it can rebound. Here's what investors should know about MU.

iQIYI Stock Is Facing Multiple Headwinds Ahead of Its Results

By Chris Lau, InvestorPlace Contributor

Ahead of iQIYI earnings, investors have high expectations that the company will report strong results. BUt IQ stock is risky.

Load More